MX2016001683A - Combinaciones de inhibidores de quinasa pim. - Google Patents

Combinaciones de inhibidores de quinasa pim.

Info

Publication number
MX2016001683A
MX2016001683A MX2016001683A MX2016001683A MX2016001683A MX 2016001683 A MX2016001683 A MX 2016001683A MX 2016001683 A MX2016001683 A MX 2016001683A MX 2016001683 A MX2016001683 A MX 2016001683A MX 2016001683 A MX2016001683 A MX 2016001683A
Authority
MX
Mexico
Prior art keywords
combination
kinase inhibitor
pim kinase
treatment
inhibitor compound
Prior art date
Application number
MX2016001683A
Other languages
English (en)
Inventor
Zhu Alexander Cao
Abdel Saci
K Gary J Vanasse
Joseph Daniel Growney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016001683A publication Critical patent/MX2016001683A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

La presente invención se refiere a un compuesto inhibidor de quinasa Pim que se puede utilizar solo o en una combinación farmacéutica. Una de tales combinaciones comprende (a) un compuesto inhibidor de JAK, (b) un compuesto inhibidor de quinasa Pim, y, opcionalmente, al menos un vehículo farmacéuticamente aceptable para uso simultáneo, separado o secuencial, en particular para el tratamiento de un neoplasma mieloide o leucemia; una composición farmacéutica que comprende tal combinación; el uso de tal combinación para la preparación de un medicamento para el tratamiento de la neoplasia mieloide o leucemia; un paquete o producto comercial que comprende tal combinación como una preparación combinada para uso simultáneo, separado o secuencial; y a un método de tratamiento de un mamífero, especialmente un ser humano.
MX2016001683A 2013-08-08 2014-08-07 Combinaciones de inhibidores de quinasa pim. MX2016001683A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361863659P 2013-08-08 2013-08-08
US201361912856P 2013-12-06 2013-12-06
US201461987664P 2014-05-02 2014-05-02
PCT/IB2014/063781 WO2015019320A1 (en) 2013-08-08 2014-08-07 Pim kinase inhibitor combinations

Publications (1)

Publication Number Publication Date
MX2016001683A true MX2016001683A (es) 2016-05-02

Family

ID=51355592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001683A MX2016001683A (es) 2013-08-08 2014-08-07 Combinaciones de inhibidores de quinasa pim.

Country Status (12)

Country Link
US (3) US20160175293A1 (es)
EP (1) EP3030237A1 (es)
JP (2) JP2016527305A (es)
KR (1) KR20160040196A (es)
CN (1) CN105611928A (es)
AU (3) AU2014304126A1 (es)
BR (1) BR112016002311A2 (es)
CA (1) CA2917936A1 (es)
HK (1) HK1222539A1 (es)
MX (1) MX2016001683A (es)
RU (1) RU2016107813A (es)
WO (1) WO2015019320A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
EP3432886B1 (en) 2016-03-25 2021-06-02 University of Maryland, Baltimore County Pim kinase inhibitors in combination with rna splicing modulators/inhibitors for treatment of cancers
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
JP2022502491A (ja) * 2018-09-25 2022-01-11 インパクト バイオメディシンズ インコーポレイテッドImpact Biomedicines, Inc. 骨髄増殖性疾患の治療法
EP3924351A4 (en) 2019-02-12 2022-12-21 Sumitomo Pharma Oncology, Inc. FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PT2344474E (pt) * 2008-09-02 2015-12-28 Novartis Ag Derivados de picolinamida como inibidores de cinase
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2012044936A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
EP3030237A1 (en) 2016-06-15
AU2019201169A1 (en) 2019-03-07
CA2917936A1 (en) 2015-02-12
KR20160040196A (ko) 2016-04-12
AU2017210520A1 (en) 2017-08-17
WO2015019320A1 (en) 2015-02-12
RU2016107813A (ru) 2017-09-14
JP2016527305A (ja) 2016-09-08
RU2016107813A3 (es) 2018-05-23
JP2019038821A (ja) 2019-03-14
US20160175293A1 (en) 2016-06-23
BR112016002311A2 (pt) 2017-08-01
CN105611928A (zh) 2016-05-25
US20190290627A1 (en) 2019-09-26
HK1222539A1 (zh) 2017-07-07
AU2014304126A1 (en) 2016-02-11
US20170368044A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MY176235A (en) Compounds that inhibit mcl-1 protein
MX2016001683A (es) Combinaciones de inhibidores de quinasa pim.
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
TN2015000278A1 (en) Autotaxin inhibitors
PH12016500094A1 (en) Autotaxin inhibitors
MX366899B (es) Nuevos compuestos.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
GB201118656D0 (en) New compounds
PH12016501122A1 (en) Delayed release compositions of linaclotide
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
MX2014013089A (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MY179509A (en) Piperazine derivatives having multimodal activity against pain
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
MX362905B (es) Tratamiento de combinacion.
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.